These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30065794)

  • 21. In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates.
    Lee H; Roh KH; Hong SG; Shin HB; Jeong SH; Song W; Uh Y; Yong D; Lee K
    Ann Lab Med; 2016 Mar; 36(2):138-44. PubMed ID: 26709261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an
    Rico Caballero V; Almarzoky Abuhussain S; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Efficacy of Doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-Test.
    Gilani M; Munir T; Latif M; Rehman S; Ansari M; Hafeez A; Najeeb S; Saad N; Gilani M
    J Coll Physicians Surg Pak; 2015 Oct; 25(10):726-9. PubMed ID: 26454387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
    Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of Colistin-Ampicillin/Sulbactam Combination Efficacy in Imipenem-Resistant Acinetobacter baumannii Strains].
    Cıkman A; Ceylan MR; Parlak M; Karahocagil MK; Berktaş M
    Mikrobiyol Bul; 2013 Jan; 47(1):147-51. PubMed ID: 23390912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the antimicrobial resistance profiles of WHO critical priority list bacterial strains.
    Havenga B; Ndlovu T; Clements T; Reyneke B; Waso M; Khan W
    BMC Microbiol; 2019 Dec; 19(1):303. PubMed ID: 31870288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W; Linasmita P
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical laboratory approach to evaluate efficacy of amikacin. Reevaluation of in vitro MIC break points in disc susceptibility test].
    Uete G; Matsuo K; Uete T
    Jpn J Antibiot; 1992 May; 45(5):489-501. PubMed ID: 1512934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data.
    Lõivukene K; Sepp E; Adamson V; Mitt P; Kallandi U; Otter K; Naaber P
    Scand J Infect Dis; 2006; 38(11-12):1001-8. PubMed ID: 17148068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
    He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa.
    Chatzimoschou A; Simitsopoulou M; Antachopoulos C; Walsh TJ; Roilides E
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2198-205. PubMed ID: 25645829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.